Only Novo's CagriSema is filed with the FDA so far. Lilly plans to submit retatrutide in early 2027, and Structure's daily pill aleniglipron heads into Phase 3.
Recap by typeshit. Full story at qz.com.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
Men's Health argues that wider access to peptides does not automatically make them safer, and looks at where the policy could go from here.
The new ACOG practice advisory cites thin safety data and also urges caution while breastfeeding, especially with preterm and newborn infants.
Loading…